INTRODUCTION
============

Bloodstream infection (BSI) is the most relevant infections in patients undergoing hematopoietic stem cell transplant (HSCT) with high morbidity and mortality[@B1]. Until recently, gram-positive bacteria (GPB) were the most common agents causing BSI in these patients; moreover, in the last years there has been an increase of gramnegative bacteria (GNB) in several hospitals[@B2].

Despite the increase in the number of allogeneic (allo) HSCT patients with early discharge and outpatient autologous (auto) transplantation programs; there is a lack of studies evaluating the safety of treating infections in HSCT outpatients.

The objective of this study was to evaluate the etiological agents causing BSI in HSCT outpatients as well as the risk factors associated with hospitalization and 30-day mortality.

METHODS
=======

The Hospital das Clinicas is a teaching hospital with 2,200-beds and is a reference center for auto and allo-HSCT in Brazil. The outpatient unit is open from 7 am to 7 pm, every day of the week, including weekends. All patients submitted to HSCT were hospitalized at the time of transplantation.

Records of outpatients presenting with positive blood cultures over a 5-year period (January 2005 to December 2008) were reviewed. This study was approved by the Ethics Committee of the Hospital das Clinicas of University of Sao Paulo.

The BSI definition used were patients with positive blood culture collected through the central venous catheter (CVC) or a peripheral access during a period in which patients had fever and physicians had described antibiotics. The end points evaluated were hospitalization and 30-day mortality BSI onset. Clinical and demographic variables at the time of BSI, such as gender, age, underlying disease, length of hospitalization, type of HSCT, CVC (type and withdrawal), the presence of mucositis or graft-versus-host disease (GVHD) and Multinational Association of Supportive Care in Cancer (MASCC) risk index score were evaluated. Hospitalizations depended on the clinical status, and when possible, the treatment was administered in the outpatient unit in which blood cultures were indicated in the presence of fever, hemodynamic instability or any infectious symptoms.

Microorganism identification and antimicrobial susceptibility test was performed using Vitek^®^ (laboratory BioMérieux) and disk diffusion test followed the updated recommendations of CLSI (Clinical and Laboratory Standards Institute).

Data were analyzed using the softwares Epi Info version 3.5.1 and STATA. The two-tailed Fisher\'s exact test was used for categorical variables and the Wilcoxon test was used for continuous variables. Logistic regression models were developed to identify factors associated with hospitalization within 21 days onset of BSI and 30-day mortality onset BSI. All non-overlapping variables with p \< 0.1 on bivariate analysis were entered into a stepwise forward model. A p-value \<0.05 was considered statistically significant.

RESULTS
=======

A total of 743 HSCT outpatients were evaluated during the study period and the records of 146 of them were analyzed. A total of 235 BSI episodes were identified among the 146 patients evaluated, being 207 (88%) monomicrobial and 28 (12%) polymicrobial. The hospitalization occurred in 61 (26%) episodes, the more frequent reason was septic shock, 18/61 (31%) ([Table 1](#t1){ref-type="table"}). A total of 266 agents were isolated, being 175 (66.7%) gram-negative bacteria (GNB), 80 (30.3%) gram-positive bacteria (GPB) and 9 (3.4%) fungi ([Table 1](#t1){ref-type="table"}).

###### Clinical characteristic of 235 bloodstream infection episodes in 146 HSCT outpatients in Hospital das Clinicas, Brazil

  Characteristic                                                               N (%)                                                                                
  ---------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------- ----------
  **Mucositis**                                                                63 (25)                                                                              
  **Grade of mucositis (%)**                                                                                                                                        
                                                                               I                                              25 (48)                               
                                                                               II                                             15 (29)                               
                                                                               III                                            10(19)                                
                                                                               IV                                             2 (4)                                 
  **GVHD (%)**                                                                                                                                                      
                                                                               Skin                                           58 (70)                               
                                                                               Gut                                            48 (60)                               
                                                                               Lung                                           5 (6)                                 
  **Grade of GVHD (%)**                                                                                                                                             
                                                                               I                                              12 (44)                               
                                                                               II                                             4 (15)                                
                                                                               III                                            8 (30)                                
                                                                               IV                                             3 (11)                                
  Severe neutropenia (\<100 cells/mm^3^) (%)                                   63 (28)                                                                              
  **Neutropenia**                                                                                                                                                   
                                                                               ANC, median (range) (cells/mm^3^)              2,300(0-37,600)                       
                                                                               Length of neutropenia, median (range) (days)   6 (1-30)                              
  **Imune recovery after transplant (%)**                                                                                                                           
                                                                               Until 30 days after BMT                        91 (39)                               
                                                                               30 days to 100 days after BMT                  92 (39)                               
                                                                               After 30 days of BMT                           52 (22)                               
  **CVC (%)**                                                                                                                                                       
                                                                               Non-tunneled                                   2 (1)                                 
                                                                               Tunneled                                       191 (84)                              
                                                                               Totally implantable                            9 (4)                                 
                                                                               Absence                                        25 (11)                               
  **CVC infection (%)**                                                        19 (9)                                                                               
  **CVC withdrawal (%)**                                                       66 (33)                                                                              
  **Previous usage of antimicrobials (%)**                                     190 (81)                                                                             
                                                                               Until 30 days before collection (%)            187 (80)                              
                                                                               On time of collection (%)                      139 (60)                              
                                                                               Cefepime                                       113 (58)                              
                                                                               Levofloxacin                                   52 (27)                               
                                                                               Meropenem                                      105 (54)                              
                                                                               Teicoplanin                                    136 (70)                              
  **BSI agents (%)**                                                                                                                                                
                                                                               Most frequent Gram-positive bacteria           80 (30)                               
                                                                                                                              *Staphylococcus coagulase negative*   31 (12%)
                                                                                                                              *Enterococcus faecium*                9 (3%)
                                                                                                                              *Micrococcus spp*                     9 (3%)
                                                                                                                              *Staphylococcus aureus*               7 (3%)
                                                                                                                              *Streptococcus pneumoniae*            4 (1%)
                                                                               Most frequent Gram-negative bacteria           175 (67)                              
                                                                                                                              *Stenotrophomonas maltophilia*        39 (15%)
                                                                                                                              *Acinetobacter spp*                   24 (9%)
                                                                                                                              *Pseudomonas aeruginosa*              15 (6%)
                                                                                                                              *Burkholderia cepacia*                13 (5%)
                                                                                                                              *Klebsiella spp*                      12 (4%)
                                                                                                                              *Enterobacter cloacae*                11 (4%)
                                                                                                                              *Serratia marcescens*                 9 (3%)
                                                                                                                              *Agrobacterium spp*                   8 (3%)
  Fungi                                                                        9 (3)                                                                                
                                                                                                                              *Candida spp*                         6 (2%)
  **Cultures (%)**                                                                                                                                                  
                                                                               Monomicrobial                                  207 (88)                              
                                                                               Polymicrobial                                  28 (12)                               
  **Hospitalization up to 21 days after culture (%)**                          61 (26)                                                                              
  **Hospitalization reasons (%)**                                                                                                                                   
                                                                               infection complications                        8 (14)                                
                                                                               Sepsis                                         12 (14)                               
                                                                               Sepsis shock                                   18 (31)                               
                                                                               Others                                         20                                    
  **New infection (%)**                                                        84 (36)                                                                              
  **Length of positive culture until hospitalization, media (range) (days)**   3.3 (0-21)                                                                           
  **MASCC, median (range)**                                                    22 (8-26)                                                                            
  **Death up to 30 days (%)**                                                  22 (10)                                                                              
  **Time between positive culture and death, median (range) (days)**           42 (0-995)                                                                           

CVC: central venous catheter; MASCC: Multinational Association for Supportive Care in Cancer Risk Index, GVHD: Graft-Versus-Host Disease. Others BSI agents: *Leuconostoc spp, Bacillus spp, Sphingomonas paucimobilis, Chryseobacterium spp, E.coli, Leuconostoc spp, Aeromonas spp. O*ther: myelodysplastic syndrome (25%), Fanconi anemia (25%), myelofibrosis (12.5%), Ewing' sarcoma (6.25%), Krabbe disease (6.25%), germinal cells tumor (6.25%), adrenoleukodystrophy (6.25%), seminoma (6.25%).

Resistance to cefepime in *P. aeruginosa* was identified in only 2/15 (13%) of the isolated agents, to imipenem in 2/14 (14%), and to meropenem in 3/10 (27%). Among *Enterobacter cloacae,* resistance to cefepime occurred in 3/11 (27%) cases, no carbapenem resistance was identified. Among *Acinetobacter spp,* resistance to cefepime occurred in 3/24 (14%) and resistance to imipenem in 2/24 (8%). Resistance to levofloxacin occurred in 1/39 (3%) and to trimethoprim-sulfamethoxazole in 3/39 (8%) of *S. maltophilia* isolates. Resistance to vancomycin was identified in 7/9 (78%) of *E. faecium* BSI. Gram-negative bacteria accounted for 72% of bloodstream infections in allogeneic transplants and 62% of autologous ones (p=0.12). The mean time between transplantation and BSI was higher among allogeneic than autologous HSCT patients (145.5 and 44.1 days, respectively), probably because allogeneic patients remain hospitalized for longer periods after transplantation and at higher risk of infection after discharge. Death in 30 days were 8.5% in autologous and 15.2% in allogenic HSCT (*p*=0.17). Median time between positive culture and death in days were 56 days in gram-negative and 27 days in gram-positive infections.

The bivariate analysis showed that previous use of levofloxacin, MASCC score higher than 21 and autologous (auto)-HSCT were protector factors and neutropenia was a risk factor for hospitalization. Moreover, only auto-HSCT remained as protector in the multivariate analysis ([Table 2](#t2){ref-type="table"}). The bivariate analysis showed that the CVC withdrawal, and MASCC higher than 21 points were protector factors for death ([Table 2](#t2){ref-type="table"}). Moreover, only MASCC score remained as protector ([Table 2](#t2){ref-type="table"}).

###### Risk factors for hospitalization and death in 30 days among 235 episodes of BSI in HSCT outpatients patients.

  Variables                                               Hospitalization N (%)   Bivariate Analysis RR (CI 95%)   P-value            Multivariate analysis OR (CI 95%)   p-value             
  ------------------------------------------------------- ----------------------- -------------------------------- ------------------ ----------------------------------- ------------------- -------
  Previous usage of levofloxacin (%)                      44 (85)                 8 (16)                           0.82 (0.70-0.97)   0.030                               0.56 (0.23-1.40)    0.22
  Autologous BMT (%)                                      74 (88)                 10 (12)                          0.75 (0.65-0.86)   0.0001                              0.23 (0.11-0.68)    0.005
  Bacteremia due to gram-positive\* (%)                   46 (66)                 24 (34)                          1.17 (0.97-1.41)   0.050                               1.16 (0.51-2.65)    0.71
  Mucositis (%)                                           43 (68)                 20 (32)                          1.11 (0.91-1.33)   0.16                                                    
  Severe neutropenia (%)                                  38 (60)                 25 (40)                          1.28 (1.02-1.60)   0.007                               1.67 (0.71-3.92)    0.24
  CVC withdrawn (%)                                       52 (79)                 14 (21)                          0.91 (0.77-1.07)   0.19                                                    
  Length of BMT until bacteremia, median (range) (days)   174                     61                               60 (6-746)         0.21                                                    
  ANC. median (range) cels/mm^3^                          164                     61                               220 (0-23,400)     0.12                                                    
  MASCC. median                                           174                     59                               18 (8-26)          \< 0.0001                                               
  MASCC score higher than 21 (%)                          101 (82)                23 (18)                          0.82 (0.70-0.96)   0.008                               0.55 (0.27-1.13)    0.10
                                                          Death N (%)             Bivariate Analysis RR (CI 95%)   P-value            Multivariate analysis OR (CI 95%)   p-value             
  Yes                                                     No                                                                                                                                  
  Age. (median)                                           32                      38                                                  0.29                                                    
  Previous usage of levofloxacin (%)                      26 (93)                 2 (7)                            0.89 (0.77-1.03)   0.17                                                    
  Autologous BMT (%)                                      54 (92)                 5 (8)                            0.93 (0.86-1.01)   0.17                                3.73 (0.90-15.28)   0.06
  Bacteremia Gram-positive\* (%)                          39 (81)                 9(19)                            1.11 (0.95-1.29)   0.10                                                    
  Bacteremia Gram-negative (%)                            81(90)                  19 (9)                           0.91 (0.79-1.0)    0.15                                                    
  Fungi                                                   4 (100)                 0                                0.87 (0.81-0.92)   0.58                                                    
  Mucositis (%)                                           38 (83)                 8 (17)                           1.02 (0.92-1.12)   0.41                                                    
  GVHD (%)                                                34 (83)                 7(17)                            1.07 (0.92-1.25)   0.21                                                    
  Severe neutropenia (%)                                  32 (82)                 7 (18)                           1.06 (0.90-1.23)   0.28                                                    
  CVC withdrawal (%)                                      34 (97)                 1 (3)                            0.87 (0.79-0.97)   0.050                               40 (0.07-2.38)      0.32
  ANC, median (range) (cels/mm^3^)                        2,350                   1,250                                               0.54                                                    
  Duration of neutropenia. (days, mean)                   3.4                     4.5                                                                                                         0.43
  MASCC. median                                           21                      16                                                  0.0001                              0.78 (0.68-0.90)    0.001
  MASCC score higher than 21 (%) \*\*                     127 (88)                18 (12)                          0.90 (0.83-1.02)   0.07                                                    
  Shock                                                   11 (27)                 29 (73)                          1.70 (0.43-6.69)   0.34                                                    

CVC: central venous catheter; MASCC: Multinational Association for Supportive Care in Cancer Risk Index. GVHD: Graft-Versus-Host Disease

DISCUSSION
==========

We observed a high proportion of GNB-BSI in our HSCT outpatient unit. The predominance of GNB has been reported by Brazilian studies that evaluated HSCT inpatients[@B3]. In our casuistic, BSI episodes occurred mainly in the first 100 days after the transplantation, similarly to other studies in the literature[@B1] ^,^ [@B2] and *S. maltophilia* was the most frequent agent in both monomicrobial and polymicrobial BSI. In general, this agent causes outbreaks in BMT settings[@B4]. Moreover, as in our hospital, a recent study has shown that *S. maltophilia* and *P. aeruginosa* were the most commonly isolated GNB in HSCT patients[@B5]. We observed a high frequency of infection caused by waterborne bacteria (18%). Infection by these agents is rare even in neutropenic patients[@B6]. However, our service recommends the protection of the CVC\'s lumen with a plastic dressing to prevent exposure to tap water, a potential source of waterborne agents but it was not possible to assess patients' compliance with this recommendation. Thus, inappropriate care of CVC at home during baths might explain this finding[@B7].

In our study the 30-day mortality onset BSI was 10% and hospitalization occurred in 26% of patients. Moreover, the multivariate analysis showed that autologous HSCT was the only independent protector factor for hospitalization. MASCC score and CVC withdrawal were protective factors for death in the bivariate analysis. In addition, only MASCC score higher than 21, remained as protector factor in the multivariate analysis. Unfortunately, in our study the catheter removal was not carried out as recommended in the literature because of the difficulty of venous access.

In the literature the presence of infection is a major cause of death in HSCT patients[@B1]. Ortega et al showed that 10% of HSCT inpatients with infection evolved to death[@B6]. Therefore, the proportion of deaths in the present study in outpatients was similar to that described in BSI HSCT inpatients[@B8]. Vancomycin-resistant enterococcus (VRE) mortality in HSCT patients ranges from 7% to 34%[@B9] similar to our findings. In contrast, authors have reported a high mortality of BSI caused by carbapenem-resistant GNB in HSCT[@B10].

In conclusion, GNB were the most frequent agents causing BSI in HSCT outpatients in our hospital; hospitalization rate was low and auto-HSCT was a protector factor for hospitalization and the MASCC score higher than 21 points for 30-day mortality.
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